Taysha Gene Therapies Inc
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
It is not solvency that is the problem — the cash lasts into 2028, a going-concern qualification is deliberately absent. The risk is the single-drug bet: if the FDA says yes to TSHA-102, the value can multiply; if it says no or demands a further trial, the only pillar falls, and the full cash box merely lengthens the road down. On top comes ongoing dilution. Whoever gets in should have understood this binary bet — not follow the red label and not the price jump. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Taysha is the opposite of what the red warning sign suggests: more solid financially than the insolvency scanner implies ($276.6 million in cash, runway into 2028, no going-concern qualification) — and nonetheless one of the riskiest bets on the market. Because the entire value hangs on a single drug, TSHA-102 against Rett syndrome, and on a single FDA decision. No revenue, a growing loss, constant dilution — set against strong medical designations and encouraging early data. A binary event. Not investment advice.
Financial position & liquidity
Surprisingly solid for a clinical biotech: $276.6 million in cash (March 31, 2026), runway per the report "into 2028", and in 2025 the cash balance even rose by $180.9 million. Unlike comparable warning-scanner hits, there is NO going-concern qualification from the auditor.
Science & approval path
TSHA-102 carries strong FDA designations (Breakthrough Therapy, RMAT, Fast Track, Orphan Drug) and showed an early response rate of 83 percent (5 of 6 patients, high dose, May 2025 data cut). The design of the pivotal REVEAL trial is aligned with the FDA. But the trial is small and single-arm — the outcome remains open.
Cluster risk (a single drug)
TSHA-102 is, per the company's own report, the "sole product candidate in clinical development". The entire company value hangs on one molecule and a single FDA decision — without a second pillar as a safety net. A no, or the demand for a further trial (as in the Replimune case), would let the only load-bearing pillar give way.
Dilution & financing
Without revenue, Taysha finances itself almost entirely through new shares: $274.6 million fresh in 2025 alone (of which $264.0 million through shares), about 287 million shares plus pre-funded warrants. The capital need does not end with the cash lasting into 2028 — an approval process and building commercial operations are likely to cost further shares.
Scanner finding & market
The warning scanner "Going Concern (Distress-Proxy)" flags Taysha for real (Altman Z near zero, Piotroski 4 of 9, rating D) — but the metric is structurally strict for a revenue-less lab. At the same time a strong price rally is under way (plus 178.7 percent over twelve months, data as of July 13, 2026) and about 96 percent of the shares are held by institutions: the market takes the bet seriously but has not decided it.
Worth Noting
Taysha reports on a calendar-year basis (fiscal year ends December 31). Program and trial updates appear partly mid-year via press release — when in doubt, reconcile against the filing periods.
The financing chart sums the three 2025 capital sources per the 10-K (May 2025 placement $215.6 million, Trinity loan $50.0 million Tranche A, ATM sale $48.4 million); the reported net financing inflow for 2025 was $274.6 million.
Price and scanner figures are dated July 13, 2026 (plus 178.7 percent over twelve months; about 287 million shares); analyses are evergreen, daily prices are not a buy argument.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at TSHA since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 2.80 $ to 7.00 $ · Last price: 5.20 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc TSHA | 1.5 | – | -0.6 | 100.0 | -1,774.4 | 17.3 | 77.9 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 59.1 | 20.7 | 9.6 | 35.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | – | -1 | -1 | -0.03 | 0 | 0 | 0 |
| 2020 | 0 | -43 | -43 | -2.43 | -31 | 251 | 259 |
| 2021 | 0 | -173 | -175 | -4.64 | -117 | 95 | 214 |
| 2022 | 3 | -126 | -166 | -3.78 | -88 | 1 | 126 |
| 2023 | 15 | -72 | -112 | -0.96 | -73 | 75 | 173 |
| 2024 | 8 | -91 | -89 | -0.36 | -81 | 72 | 160 |
| 2025 | 10 | -111 | -109 | -0.34 | -93 | 247 | 343 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | -135.90 | 2 | -43.90 | -929.00 | -18 | -18 |
| 2025: Q1 | -0.08 | – | 2 | -32.50 | -935.20 | -22 | -22 |
| 2025: Q2 | -0.09 | – | 2 | 78.60 | -1,353.60 | -20 | -20 |
| 2025: Q3 | -0.09 | – | 0 | -100.00 | – | -24 | -24 |
| 2025: Q4 | -0.09 | – | 6 | 171.30 | -507.80 | -27 | -27 |
| 2026: Q1 | -0.12 | – | 0 | -100.00 | – | -41 | -44 |
| 2026: Q2 | -0.13 | -44.40 | 0 | -100.00 | – | -40 | -40 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 14 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Mark Minervini: Trend Criteria — 1 Month
- Power Trend
- RS Leader (≥90)
- Stan Weinstein: Checklist
- Stan Weinstein: Stage 2
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.47 | -0.58 – -0.38 | 2 | -49.1% | 5 |
| 12/31/2027 | -0.46 | -0.53 – -0.43 | 20 | 2.4% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Taysha ist ein klinisches Gentherapie-Unternehmen; sein Wert hängt am Wirkstoff TSHA-102 (AAV9) gegen das Rett-Syndrom, nicht an KI. In den ausgewerteten Filings taucht KI ausschließlich als Randthema auf — als internes Arbeitswerkzeug der Mitarbeiter und als allgemeines Compliance-/Datenschutz-Risiko. KI ist weder Umsatzquelle noch ein konkret auf das eigene Geschäftsmodell bezogenes Wettbewerbsrisiko. Damit greift keine der Kategorien „verkauft“, „nutzt“ oder „bedroht“; es bleibt ein dokumentierter Neutral-Befund.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Beschäftigten und Mitarbeiter nutzen generative Technologien der künstlichen Intelligenz (KI) für ihre Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und sonstigen Datenschutzpflichten.
10-K · 2026-03-19 · View SEC filing
„Governments have passed and are likely to pass additional laws and regulations regulating AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits."
Regierungen haben zusätzliche Gesetze und Vorschriften zur Regulierung von KI erlassen und werden dies wahrscheinlich weiter tun. Unsere Nutzung dieser Technologie könnte zusätzliche Compliance-Kosten, aufsichtsbehördliche Untersuchungen und Verfahren sowie Klagen nach sich ziehen.
10-K · 2026-03-19 · View SEC filing
Filings Reviewed: 10-K 2026-03-19 · 10-K 2025-02-26 · 10-Q 2026-05-06 · 10-Q 2025-11-04 · 10-Q 2025-08-12 · 10-Q 2025-05-15
Rated on July 14, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 57.5%
- More than 10% revenue growth is expected for the coming year 1,508.8%
- Share count grows by less than 3% a year 93.7%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -942.8%
- Gross margin at 40% or higher and without meaningful erosion 100.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 302 m net cash
- Operating cash flow covers the profits of the last three years 63 m
- Return on capital at 15% or higher, or up versus two years ago -34.9%
- Insiders hold at least 10% or are net buyers 10.7%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 42.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 42.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -44.1%
- ROCE > 15% -34.9%
- Expected return > 10% 33.1%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Taysha Gene Therapies, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf Entwicklung und Vermarktung von AAV-basierten Gentherapien zur Behandlung schwerer monogener Erkrankungen des zentralen Nervensystems.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 99
- Headquarters
- Dallas, TX
- Address
- 3000 Pegasus Park Drive, 75247 Dallas, United States
- Phone
- 214 612 0000
- Website
- tayshagtx.com
- IPO Date
- 09/24/2020
- ISIN
- US8776191061
Management
| Name | Title | Birth Year |
|---|---|---|
| Sean P. Nolan | CEO & Chairman | 1968 |
| Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 1967 |
| Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 1978 |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | – |
| Michael B. Johannesen | Chief Legal Officer & Corporate Secretary | 1966 |
| Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | – |
| Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer | – |
| Sean McAuliffe | Chief Business Officer | – |
| Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | – |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/11/2026 Taysha Gene Therapies, Inc. (TSHA): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.